Stock DNA
Pharmaceuticals & Biotechnology
AED 31,444 Million (Mid Cap)
18.00
NA
0.00%
-0.37
8.51%
1.54
Revenue and Profits:
Net Sales:
6,993 Million
(Quarterly Results - Jun 2025)
Net Profit:
524 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-7.29%
0%
-7.29%
6 Months
-0.37%
0%
-0.37%
1 Year
-23.5%
0%
-23.5%
2 Years
0%
0%
0.0%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
PureHealth Holding Pjsc for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
43.00%
EBIT Growth (5y)
-27.07%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.36
Sales to Capital Employed (avg)
1,388.23
Tax Ratio
3.66%
Dividend Payout Ratio
20.06%
Pledged Shares
0
Institutional Holding
0.01%
ROCE (avg)
9.89%
ROE (avg)
7.13%
Valuation key factors
Factor
Value
P/E Ratio
18
Industry P/E
Price to Book Value
1.57
EV to EBIT
12.78
EV to EBITDA
6.99
EV to Capital Employed
1.91
EV to Sales
0.91
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
14.92%
ROE (Latest)
8.51%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot : Mar 2025
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.01%)
Strategic Entities with highest holding
Highest Public shareholder
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
25,848.20
16,398.90
57.62%
Operating Profit (PBDIT) excl Other Income
3,471.20
-252.30
1,475.82%
Interest
847.60
117.50
621.36%
Exceptional Items
99.30
-8.70
1,241.38%
Consolidate Net Profit
1,715.70
965.00
77.79%
Operating Profit Margin (Excl OI)
73.90%
-74.20%
14.81%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 57.62% vs 33.38% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 77.79% vs -77.26% in Dec 2023
About PureHealth Holding Pjsc 
PureHealth Holding Pjsc
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






